ChartMill · Oct 28, 2026
US Top Movers: Biggest Gainers and Decliners in Today's Session
Today's US market movers: top gainers and decliners ranked by percentage change, with double-digit moves on both sides.
NASDAQ · INBX
Healthcare · Biotechnology
$83.30
Down-$5.64 (-6.77%)
Updated Nov 16, 2026, 11:57 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · INBX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 13, 2026
INBX closed at $83.30 after 20 trading sessions, down 7.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | $87.91 | $87.91 | $80.68 | $83.30 | 245.9K |
| Nov 12, 2026 | $88.56 | $91.13 | $86.00 | $87.745 | 226.49K |
| Nov 11, 2026 | $92.38 | $93.48 | $89.30 | $90.59 | 165.74K |
| Nov 10, 2026 | $90.31 | $92.895 | $89.99 | $90.61 | 100.3K |
| Nov 9, 2026 | $86.39 | $93.45 | $84.825 | $91.74 | 185.74K |
| Nov 6, 2026 | $80.68 | $85.58 | $79.47 | $84.52 | 220.25K |
| Nov 5, 2026 | $86.00 | $86.81 | $79.35 | $80.28 | 242.33K |
| Nov 4, 2026 | $83.95 | $87.13 | $82.03 | $86.76 | 190.22K |
| Nov 3, 2026 | $71.16 | $83.00 | $71.16 | $81.08 | 600.24K |
| Nov 2, 2026 | $72.45 | $73.49 | $70.87 | $72.16 | 234.38K |
| Oct 30, 2026 | $72.04 | $73.03 | $66.80 | $71.78 | 438.83K |
| Oct 29, 2026 | $73.75 | $75.715 | $71.75 | $73.65 | 358.74K |
| Oct 28, 2026 | $94.55 | $96.785 | $69.2701 | $73.29 | 1.19M |
| Oct 27, 2026 | $88.52 | $99.8838 | $88.52 | $95.66 | 374.22K |
| Oct 26, 2026 | $93.80 | $94.46 | $86.92 | $88.61 | 251.18K |
| Oct 23, 2026 | $96.96 | $96.99 | $92.50 | $93.38 | 176.22K |
| Oct 22, 2026 | $96.94 | $100.1978 | $94.04 | $97.10 | 249.51K |
| Oct 21, 2026 | $98.10 | $99.82 | $93.002 | $98.19 | 239.32K |
| Oct 20, 2026 | $89.07 | $96.50 | $88.99 | $95.30 | 221.43K |
| Oct 19, 2026 | $90.43 | $92.98 | $88.21 | $89.79 | 156.06K |
The latest Smart Investors Daily articles mentioning INBX.
Company
Market Activity
Research & News
INBX research
Company profile and research snapshot.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 16, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 8, 2026 | Stifel | Buy | — |
| Aug 22, 2025 | JMP Securities | Market Perform | — |
| May 15, 2025 | JMP Securities | Market Perform | — |
No generated briefing is available yet.
ChartMill · Oct 28, 2026
Today's US market movers: top gainers and decliners ranked by percentage change, with double-digit moves on both sides.
Yahoo · Oct 23, 2026
Inhibrx Biosciences has delivered a strong 1 year share price run, and that kind of move naturally raises the question of whether the current US$97.10 level still lines up with what its book value can support. With the stock now drawing more attention after recent biotech sector discussions, the key issue is how much of that optimism is already embedded in the balance sheet. The share price is up 69.5% over the past year, which puts real weight on whether the accounting value of Inhibrx...
Yahoo · Oct 21, 2026
Investors are always seeking some new sign, some signal that will indicate the right stock, and the right place or time to invest. They’ll chase after analyst forecasts, macro headlines, and earnings whispers – all the usual signs. But there’s one signal that really stands out: insider trading. The insiders are the company officers, the C-suite execs and Directors on the Board who have an inside view of the company’s workings. They’ve got firsthand knowledge of their companies’ operations and fi
Yahoo · Oct 14, 2026
Inhibrx Biosciences recently announced that it will present updated data on its clinical-stage candidates INBRX-106 and INBRX-109 from phase 2/3 and phase 2 studies in head and neck squamous cell carcinoma and conventional chondrosarcoma at major oncology and tumor society conferences in Europe, the US, and South Korea. This cluster of high-profile scientific presentations, with materials to be shared on the company’s investor website, highlights how Inhibrx is bringing its clinical data...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning INBX.